Our research shows that the combination of SPHK1/MMP1 knockdown and anti-PD-1 therapy produces more obvious tumor suppression and further alleviates CD8+ T-cell exhaustion, which is consistent with previous research by Poyee et al. Here, SPHK1 is linked to neoplasm.